David Kersting1,2,3, Walter Jentzen4,5,6, Miriam Sraieb4,5,6, Pedro Fragoso Costa4,5,6, Maurizio Conti7, Lale Umutlu5,6,8, Gerald Antoch6,9, Michael Nader4,5,6, Ken Herrmann4,5,6, Wolfgang Peter Fendler4,5,6, Christoph Rischpler4,5,6, Manuel Weber4,5,6. 1. Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. david.kersting@uni-due.de. 2. West German Cancer Center (WTZ), Essen, Germany. david.kersting@uni-due.de. 3. German Cancer Consortium (DKTK), Essen and Dusseldorf, Germany. david.kersting@uni-due.de. 4. Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. 5. West German Cancer Center (WTZ), Essen, Germany. 6. German Cancer Consortium (DKTK), Essen and Dusseldorf, Germany. 7. Siemens Medical Solutions USA, Inc., Knoxville, TN, USA. 8. Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, 45147, Essen, Germany. 9. Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, 40225, Dusseldorf, Germany.
Abstract
BACKGROUND: In recurrent differentiated thyroid cancer patients, detectability in 124I PET is limited for lesions with low radioiodine uptake. We assess the improvements in lesion detectability and image quality between three generations of PET scanners with different detector technologies. The results are used to suggest an optimized protocol. METHODS: Datasets of 10 patients with low increasing thyroglobulin or thyroglobulin antibody levels after total thyroidectomy and radioiodine therapies were included. PET data were acquired and reconstructed on a Biograph mCT PET/CT (whole-body, 4-min acquisition time per bed position; OSEM, OSEM-TOF, OSEM-TOF+PSF), a non-TOF Biograph mMR PET/MR (neck region, 4 min and 20 min; OSEM), and a new generation Biograph Vision PET/CT (whole-body, 4 min; OSEM, OSEM-TOF, OSEM-TOF+PSF). The 20-min image on the mMR was used as reference to calculate the detection efficacy in the neck region. Image quality was rated on a 5-point scale. RESULTS: All detected lesions were in the neck region. Detection efficacy was 8/9 (Vision OSEM-TOF and OSEM-TOF+PSF), 4/9 (Vision OSEM), 3/9 (mMR OSEM and mCT OSEM-TOF+PSF), and 2/9 (mCT OSEM and OSEM-TOF). Median image quality was 4 (Vision OSEM-TOF and OSEM-TOF+PSF), 3 (Vision OSEM, mCT OSEM-TOF+PSF, and mMR OSEM 20-min), 2 (mCT OSEM-TOF), 1.5 (mCT OSEM), and 1 (mMR OSEM 4 min). CONCLUSION: At a clinical standard acquisition time of 4 min per bed position, the new generation Biograph Vision using a TOF-based image reconstruction demonstrated the highest detectability and image quality and should, if available, be preferably used for imaging of low-uptake lesions. A prolonged acquisition time for the mostly affected neck region can be useful.
BACKGROUND: In recurrent differentiated thyroid cancerpatients, detectability in 124I PET is limited for lesions with low radioiodine uptake. We assess the improvements in lesion detectability and image quality between three generations of PET scanners with different detector technologies. The results are used to suggest an optimized protocol. METHODS: Datasets of 10 patients with low increasing thyroglobulin or thyroglobulin antibody levels after total thyroidectomy and radioiodine therapies were included. PET data were acquired and reconstructed on a Biograph mCT PET/CT (whole-body, 4-min acquisition time per bed position; OSEM, OSEM-TOF, OSEM-TOF+PSF), a non-TOF Biograph mMR PET/MR (neck region, 4 min and 20 min; OSEM), and a new generation Biograph Vision PET/CT (whole-body, 4 min; OSEM, OSEM-TOF, OSEM-TOF+PSF). The 20-min image on the mMR was used as reference to calculate the detection efficacy in the neck region. Image quality was rated on a 5-point scale. RESULTS: All detected lesions were in the neck region. Detection efficacy was 8/9 (Vision OSEM-TOF and OSEM-TOF+PSF), 4/9 (Vision OSEM), 3/9 (mMR OSEM and mCT OSEM-TOF+PSF), and 2/9 (mCT OSEM and OSEM-TOF). Median image quality was 4 (Vision OSEM-TOF and OSEM-TOF+PSF), 3 (Vision OSEM, mCT OSEM-TOF+PSF, and mMR OSEM 20-min), 2 (mCT OSEM-TOF), 1.5 (mCT OSEM), and 1 (mMR OSEM 4 min). CONCLUSION: At a clinical standard acquisition time of 4 min per bed position, the new generation Biograph Vision using a TOF-based image reconstruction demonstrated the highest detectability and image quality and should, if available, be preferably used for imaging of low-uptake lesions. A prolonged acquisition time for the mostly affected neck region can be useful.
Entities:
Keywords:
Biograph Vision; Detectability; Differentiated thyroid cancer; Digital PET/CT; Iodine-124 PET
Authors: Casper Beijst; Jakob W Kist; Mattijs Elschot; Max A Viergever; Otto S Hoekstra; Bart de Keizer; Hugo W A M de Jong Journal: J Nucl Med Date: 2015-10-22 Impact factor: 10.057
Authors: Joyce van Sluis; Johan de Jong; Jenny Schaar; Walter Noordzij; Paul van Snick; Rudi Dierckx; Ronald Borra; Antoon Willemsen; Ronald Boellaard Journal: J Nucl Med Date: 2019-01-10 Impact factor: 10.057
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Diego Alfonso López-Mora; Albert Flotats; Francisco Fuentes-Ocampo; Valle Camacho; Alejandro Fernández; Agustí Ruiz; Joan Duch; Marina Sizova; Anna Domènech; Montserrat Estorch; Ignasi Carrió Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-10 Impact factor: 9.236
Authors: Jakob W Kist; Bart de Keizer; Manfred van der Vlies; Adrienne H Brouwers; Dyde A Huysmans; Friso M van der Zant; Rick Hermsen; Marcel P M Stokkel; Otto S Hoekstra; Wouter V Vogel Journal: J Nucl Med Date: 2015-11-25 Impact factor: 10.057
Authors: David Kersting; Stephan Settelmeier; Ilektra-Antonia Mavroeidi; Ken Herrmann; Robert Seifert; Christoph Rischpler Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923
Authors: Pedro Fragoso Costa; Walter Jentzen; Alissa Brahmer; Ilektra-Antonia Mavroeidi; Fadi Zarrad; Lale Umutlu; Wolfgang P Fendler; Christoph Rischpler; Ken Herrmann; Maurizio Conti; Robert Seifert; Miriam Sraieb; Manuel Weber; David Kersting Journal: BMC Cancer Date: 2022-08-18 Impact factor: 4.638
Authors: Elizabeth J de Koster; Taban Sulaiman; Jaap F Hamming; Abbey Schepers; Marieke Snel; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens Journal: Diagnostics (Basel) Date: 2021-03-19